News

Bio Space
biospace. com > business > how-us-pharma-manufacturing-pay-stacks-up-to-other-jobs-in-the-industry

How US pharma manufacturing pay stacks up to other jobs in the industry

1+ day, 20+ hour ago  (264+ words) The median annual wage for U. S. pharma manufacturing employees is $69, 900, a salary significantly higher than the average $51, 670 that the typical manufacturing worker brought home in 2024. Both counts surpass the $49, 500 average yearly salary for all U. S. workers, according to the most recent data…...

Symbols: btc-usd
Bio Space
biospace. com > business > serapha-takes-reverse-merger-route-to-nasdaq-with-230m-and-gene-editor-from-china

Serapha takes reverse merger route to Nasdaq with $230 M and gene editor from China

14+ hour, 5+ min ago  (292+ words) Private biotech Serapha Bio is soaring onto the public markets through a reverse merger with California's Boundless Bio, bringing with it $230 million in starting funds and a gene editing asset developed in China. The resulting entity will largely belong to…...

Symbols: btc-usd
Bio Space
biospace. com > press-releases > xella-health-launches-to-uniquely-detect-and-treat-130-often-misdiagnosed-womens-health-conditions

Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions

2+ min ago  (689+ words) Bio Space Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions With a 15, 000-Woman Waitlist, the Company Uses Proprietary AI to Close the Gender Diagnostic and Care Gap SAN FRANCISCO, June 24, 2026 /PRNewswire/ -- Xella Health today announces its…...

Symbols: btc-usd
Bio Space
biospace. com > drug-development > definiums-lsd-based-therapy-elicits-profound-efficacy-in-phase-3-depression-trial

Definium's LSD-based therapy elicits "profound' efficacy in Phase 3 depression trial

2+ day, 11+ hour ago  (338+ words) Definium Therapeutics" oral psychedelic treatment for major depressive disorder met all endpoints in a late-stage trial, sending the company"s stock soaring more than 50% when the markets opened on Monday. In the Phase 3 trial, DT120a formulation of LSDresulted in an 8. 1-point…...

Symbols: btc-usd,nasdaq:dftx,nasdaq:cmnd
Bio Space
biospace. com > business > jubilant-draws-fda-rebuke-for-delayed-mold-investigation-and-quality-unit-lapses

Jubilant draws FDA rebuke for delayed mold investigation and quality unit lapses

7+ hour, 23+ min ago  (387+ words) The FDA has hit Jubilant Hollister Stier with a warning letter after inspectors found sterility failings at the contract manufacturer's Canadian plant. FDA inspectors found Jubilant failed to investigate "mold recoveries on personnel" until months after its environmental monitoring activities…...

Bio Space
biospace. com > business > us-launches-investigation-into-german-drug-pricing-citing-unfair-r-d-burden

US launches investigation into German drug pricing, citing unfair R&D burden

5+ day, 11+ hour ago  (338+ words) The U. S. Trade Representative is investigating Germany's drug pricing policies to determine if the country's actions leave the U. S. with a disproportionate share of global R&D costs. USTR ambassador Jamieson Greer has launched the probe under Section 301 of the Trade Act…...

Symbols: btc-usd
Bio Space
biospace. com > press-releases > arletta-pharma-solutions-appoints-steve-van-os-md-as-chief-medical-officer

Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer

5+ day, 13+ hour ago  (226+ words) Steve van Os, MD Seasoned biotech executive brings more than two decades of global clinical development, medical affairs and regulatory leadership across oncology, women's health and endocrinology In his role as Chief Medical Officer, Dr. van Os will lead Arletta's…...

Symbols: btc-usd,nasdaq:vnda
Bio Space
biospace. com > business > memento-brings-home-93m-series-a-souvenir-picks-up-bispecific-for-eye-diseases

Memento brings home $93 M series A souvenir, picks up bispecific for eye diseases

5+ day, 14+ hour ago  (358+ words) Memento Medicines has bagged $93 million in series A proceeds, which the Boston biotech plans to funnel toward a newly licensed asset for retinal disorders. MMT-205 is designed to block the VEGF pathway and activate the Tie2 receptor simultaneously. Memento believes this…...

Symbols: nasdaq:ocul
Bio Space
biospace. com > press-releases > coya-therapeutics-to-present-alstars-trial-design-at-the-encals-2026-meeting

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

5+ day, 21+ hour ago  (147+ words) The details for the poster presentation, which will be presented by Tyrell Simkins, D. O. , Ph. D. , Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T Cells And Neuroinflammation In ALS Authors: Tyrell…...

Symbols: nasdaq:coya
Bio Space
biospace. com > press-releases > portal-biotechnologies-accelerates-growth-with-latest-round-led-by-nfx-expanded-darpa-contract-and-broad-adoption-across-top-pharma-and-academic-centers

Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

5+ day, 18+ hour ago  (159+ words) Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. The proprietary platform leverages mechanoporation to enable efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types…...

Symbols: btc-usd